Cielo Review
Best for: Price-sensitive patients who want flat-rate compounded semaglutide or tirzepatide on a 3-month commitment and don't require a publicly disclosed pharmacy partner or accreditation badge
Cielo (joincielo.health) is a compounded-GLP-1-only telehealth platform headquartered at 7901 4th St N, Ste 300, St. Petersburg, FL 33702. The technology and admin platform is contracted with MD Integrations for clinical care; medical services are 'delivered exclusively by independently owned and operated professional corporations or licensed medical groups' (privacy policy verbatim). Compounded semaglutide starts at $115/mo on a 3-month bundle ($149/mo monthly) and compounded tirzepatide starts at $180/mo on a 3-month bundle ($249/mo monthly) — same price any dose. No brand-name Wegovy/Zepbound, no TRT/hair/mental-health adjacencies. Florida governing law. State coverage list not publicly disclosed at the time of verification.
Medium confidence · Last verified 2026-05-15 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Cielo is one of the most affordable GLP-1 options on the market.
Score Breakdown
Drugs Offered
Cielo prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| All doses (monthly) | compounded | $149 |
| All doses (3-mo bundle) | compounded | $115 |
| All doses (monthly) | compounded | $249 |
| All doses (3-mo bundle) | compounded | $180 |
✓ Pros
- •Among the lowest 3-month-bundle prices in compounded GLP-1 segment ($115/mo semaglutide)
- •Single flat price across all doses simplifies titration planning
- •Transparent corporate address (St. Petersburg, FL) and customer-service phone published
✗ Cons
- •No publicly disclosed LegitScript, NABP .pharmacy, or HIPAA badge on home page
- •Named pharmacy partner not disclosed publicly (only 'Regulated FDA pharmacy partners')
- •State coverage list not published — cannot verify all-50-state availability
- •MD Integrations is a third-party clinical-affiliations network used by many compounded-GLP-1 brands (not a dedicated medical group), reducing structural differentiation
- •No brand-name Wegovy/Zepbound option for patients who want FDA-approved manufacturer fulfillment
- •Donation page displays '0%' next to the 10%-pledge claim (apparent discrepancy noted on home page)
Ready to start with Cielo?
Starting at $115/month. See current pricing and start your free consultation.
Sources & methodology
Our Cielo review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Cielo
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Cielo?
Starting at $115/month. See current pricing and start your free consultation.